All In Biotech

Drug Trial Radar · NCT06747416

KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors

A Phase II Multicenter, Open Label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and PK/PD Profile of Multiple Subcutaneous Injection of KN057 in Male Patients with Severe Hemophilia a or Moderate-to-Severe Hemophilia B with or Without Inhibitors

Last checked: Nov 19, 2026Latest source record: Dec 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Sep 2, 2025

Primary completion

Sep 2, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Suzhou Alphamab Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and efficacy of KN057 in adult patients with severe Hemophilia A (coagulation factor FVIII activity \<1%) or moderate-to-severe Hemophilia B (FIX activity ≤2%). Participants will be administered subcutaneously with KN057 once a week for 20 weeks. KN057 works differently than factor replacement products and will work in the presence of inhibitors. The potential for once weekly subcutaneous administration provides better convenience and compliance.

Conditions

  • Hemophilia a and B

Interventions

  • KN057Drug

    KN057 will be administered subcutaneously once a week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment emergent adverse events(TEAEs)Time frame: Week 0 up to Week 26
  2. Number of participants with abnormal laboratory findings in HematologyTime frame: Week 0 up to Week 26
  3. Number of participants with abnormal laboratory findings in Coagulation FunctionTime frame: Week 0 up to Week 26
  4. Number of participants with abnormal laboratory findings in Blood BiochemistryTime frame: Week 0 up to Week 26
  5. Number of participants with clinically significant changes in 12-lead electrocardiogramsTime frame: Week 0 up to Week 26
  6. Number of participants with clinically significant changes in vital signsTime frame: Week 0 up to Week 26
  7. Number of participants with clinically significant changes in physical examination FindingsTime frame: Week 0 up to Week 26
  8. Incidence and severity of injection site reactionTime frame: Week 0 up to Week 26

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.